Premium
Imitinab (Gleevec) in the treatment of chronic myeloid luekemia (CML)
Author(s) -
Boulos Badi M,
Jajeh Ahmad,
Ciobanu Betty,
Nawaz Ubaid,
Smiley Tracy,
Yim Barbara
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.5.a1132
Subject(s) - medicine , imatinib , philadelphia chromosome , myeloid leukemia , tyrosine kinase inhibitor , chromosomal translocation , gastroenterology , tyrosine kinase , cancer , biology , receptor , biochemistry , gene
Imitinab (Gleevec) is a Tyrosine Kinase Inhibitor. Tyrosine Kinase is the site of active phosphorylation on the fusion protein, of the translocation of chromosome nine and twenty two seen in Chronic Myeloid Luekemia (CML). Forty‐five patients diagnosed with CML were treated with Imitinab, mean age 51, years (range 20–81 years). 37 were males and 8 females, 17 African American, 13 Hispanics, 12 White and 3 others. Mean oral dose of Imitinab was 400 mg/day, median follow up was 2 years. Complete disappearance of typical BCR/ABL by FISH was seen in 20 patients (44%). Reduction of more than 50% was seen in 2 patients. 3 patients had blastic crisis prior to therapy and one with accelerated phase. All patients achieved hematological remission. The 3 patients with blastic crises died within 5 months. Resistance to Imitinab was seen in 3 patients. One case developed severe allergic reaction to the drug. Our results showed response rate in chronic phase of 75% similar to reported trials of 85–95%. Non‐compliance is an important factor for lowering rate of response. Further trials are needed.